Voyager Therapeutics

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company focused on developing treatments for patients with severe neurological diseases. Voyager Therapeutics' primary clinical candidate is VY-AADC, which is in an open-label Phase Ib clinical trial for the treatment of Parkinson's disease. Voyager Therapeutics' preclinical products include VY-SOD101 for amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau for tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and VY-NAV01 for severe chronic pain.